This Article Full Text Full Text (PDF) All Versions of this Article: 118/17/1729    most recent CIRCULATIONAHA.107.759241v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Cataliotti, A. Articles by Burnett, J. C. Search for Related Content PubMed PubMed Citation Articles by Cataliotti, A. Articles by Burnett, J. C., Jr Related Collections Cardiovascular Pharmacology Animal models of human disease Related Article

(Circulation. 2008;118:1729-1736.)
© 2008 American Heart Association, Inc.

Hypertension

Chronic Actions of a Novel Oral B-Type Natriuretic Peptide Conjugate in Normal Dogs and Acute Actions in Angiotensin II–Mediated Hypertension

Alessandro Cataliotti, MD, PhD; Horng H. Chen, MD; John A. Schirger, MD; Fernando L. Martin, MD; Guido Boerrigter, MD; Lisa C. Costello-Boerrigter, MD, PhD; Kenneth D. James, PhD; Karen Polowy, BS; Mark A. Miller, MS; Navdeep B. Malkar, PhD; Kent R. Bailey, PhD; John C. Burnett, Jr, MD

From the Cardiorenal Research Laboratory, Division of Cardiovascular Diseases and Internal Medicine (A.C., H.H.C., J.A.S., F.L.M., G.B., L.C.C.-B., K.D.J., K.P., M.A.M., N.B.M., K.R.B., J.C.B.), and Section of Biostatistics (K.R.B.), Mayo Clinic, Rochester Minn.

Correspondence to Alessandro Cataliotti, MD, PhD, Cardiorenal Research Laboratory, Mayo Clinic and Foundation, Rochester, MN 55905. E-mail cataliotti.alessandro{at}mayo.edu

Received July 24, 2007; accepted August 18, 2008.

Background— We previously reported the feasibility of an acute, orally delivered, newly developed, conjugated form of human B-type natriuretic peptide (hBNP) in normal animals. The objective of the present study was to extend our findings and to define the chronic actions of an advanced oral conjugated hBNP (hBNP-054) administered for 6 days on sodium excretion and blood pressure. We also sought to establish the ability of this new conjugate to acutely activate cGMP and to reduce blood pressure in an experimental model of angiotensin II (ANG II) –mediated hypertension.

Methods and Results— First, we developed additional novel conjugated forms of oral hBNP that were superior to our previously reported hBNP-021 in reducing blood pressure in 6 normal dogs. We then tested the new conjugate, hBNP-054, chronically in 2 normal dogs to assess its biological actions as a blood pressure–lowering agent and as a natriuretic factor. Second, we investigated the effects of acute oral hBNP-054 or vehicle in 6 dogs that received continuous infusion of ANG II to induce hypertension. After baseline determination of mean blood pressure (MAP) and blood collection for plasma hBNP and cGMP, all dogs received continuous ANG II infusion (20 ng · kg^–1 · min^–1, 1 mL/min) for 4 hours. After 30 minutes of ANG II, dogs received oral hBNP-054 (400 µg/kg) or vehicle in a random crossover fashion with a 1-week interval between dosing. Blood sampling and MAP measurements were repeated 30 minutes after ANG II administration and 10, 30, 60, 120, 180, and 240 minutes after oral administration of hBNP-054 or vehicle. In the chronic study in normal dogs, oral hBNP-054 effectively reduced MAP for 6 days and induced a significant increase in 24-hour sodium excretion. hBNP was not present in the plasma at baseline in any dogs, and it was not detected at any time in the vehicle group. However, hBNP was detected throughout the duration of the study after oral hBNP-054, with a peak concentration at 30 minutes of 1060±818 pg/mL. In the acute study, after ANG II administration, plasma cGMP was not activated after vehicle, whereas it was significantly increased after oral hBNP-054 (P=0.01 between the 2 groups). Importantly, MAP was significantly increased after ANG II throughout the acute study protocol. However, although no changes occurred in MAP after vehicle administration, oral hBNP-054 reduced MAP for >2 hours (from 138±1 mm Hg after ANG II to 124±2 mm Hg at 30 minutes, 124±2 mm Hg at 1 hour, and 130±5 mm Hg at 2 hours after oral hBNP-054; P<0.001).

Conclusions— This study reports for the first time that a novel conjugated oral hBNP possesses blood pressure–lowering and natriuretic actions over a 6-day period in normal dogs. Furthermore, hBNP-054 activates cGMP and reduces MAP in a model of acute hypertension. These findings advance the concept that orally administered chronic BNP is a potential therapeutic strategy for cardiovascular diseases such as hypertension.

---

 

CLINICAL PERSPECTIVE

Related Article:

Clinical Summaries
Circulation 2008 118: 1689-1690. [Extract] [Full Text]